Global characterization of signalling networks associated with tamoxifen resistance in breast cancer

FEBS Journal

Volumn 280, Issue 21, 2013, Pages 5237-5257

  Browne, Brigid C ^a   Hochgräfe, Falko ^b   Wu, Jianmin ^a,c   Millar, Ewan K A ^a,c,d,e   Barraclough, Jane ^a   Stone, Andrew ^a   McCloy, Rachael A ^a   Lee, Christine S ^a   Roberts, Caroline ^a   Ali, Naveid A ^a   Boulghourjian, Alice ^a   Schmich, Fabian ^f,g   Linding, Rune ^h   Farrow, Lynn ⁱ   Gee, Julia M W ⁱ   Nicholson, Robert I ⁱ   O'Toole, Sandra A ^a,c,j,k   Sutherland, Robert L ^a,c   Musgrove, Elizabeth A ^a,c   Butt, Alison J ^a,c,m   Daly, Roger J ^a,c,l   more..

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f ETH ZURICH   (Switzerland)

^g SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^h TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

ⁱ CARDIFF UNIVERSITY   (United Kingdom)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k UNIVERSITY OF SYDNEY   (Australia)

^l MONASH UNIVERSITY   (Australia)

^m National Breast Cancer Centre   (Australia)

more..

Author keywords

endocrine resistance; MARCKS; MCF7; phosphoproteomics; Yes kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROWTH FACTOR; MARCKS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE YES; RAS PROTEIN; REGULATOR PROTEIN; SMALL INTERFERING RNA; TAMOXIFEN; TYROSINE;

BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CELL METABOLISM; CELL STRAIN MCF 7; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ENDOCRINE RESISTANCE; MARCKS; MCF7; PHOSPHOPROTEOMICS; YES KINASE;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN INTERACTION MAPS; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84886038264     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12441     Document Type: Conference Paper

References (71)

1. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717.
2. Musgrove EA, &, Sutherland RL, (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9, 631-643.
3. Johnston SR, (2010) New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 16, 1979-1987.
4. Johnston SR, (2006) Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 12, 1061s-1068s.
5. Dodwell D, Wardley A, &, Johnston S, (2006) Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast 15, 584-594.
6. Bertelli G, &, Paridaens R, (2006) Optimal sequence of hormonotherapy in advanced breast cancer. Curr Opin Oncol 18, 572-577.
7. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, &, Elledge RM, (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Clin Cancer Res 10, 5670-5676.
8. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, &, Schiff R, (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68, 826-833.
9. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, &, Nicholson RI, (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044.
10. Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, &, Nicholson RI, (2007) Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 60, 1216-1221.
11. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, &, Nakshatri H, (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem 276, 9817-9824.
12. Gee JM, Robertson JF, Ellis IO, &, Nicholson RI, (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95, 247-254.
13. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, &, Chibbar R, (2005) Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 18, 250-259.
14. Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, &, Hiscox S, (2009) Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 8, 1550-1558.
15. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, MacGrogan G, Mauriac L, Katsaros D, Molina F, Theillet C, et al,. (2008) A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 14, 1744-1752.
16. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, et al,. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25, 1239-1246.
17. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, et al,. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616.
18. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Gonzalez-Angulo AM, Mills GB, Miller WR, Wu H, et al,. (2011) A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 17, 2024-2034.
19. Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC, Pinese M, Caldon CE, Schutte J, Gardiner-Garden M, et al,. (2008) Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 3, e2987.
20. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al,. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351, 2817-2826.
21. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, et al,. (2009) The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116, 303-309.
22. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, et al,. (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23, 732-740.
23. Lyng MB, Laenkholm AV, Tan Q, Vach W, Gravgaard KH, Knoop A, &, Ditzel HJ, (2013) Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study. PLoS One 8, e54078.
24. Huber-Keener KJ, Liu X, Wang Z, Wang Y, Freeman W, Wu S, Planas-Silva MD, Ren X, Cheng Y, Zhang Y, et al,. (2012) Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data. PLoS One 7, e41333.
25. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, et al,. (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16, 5222-5232.
26. Besada V, Diaz M, Becker M, Ramos Y, Castellanos-Serra L, &, Fichtner I, (2006) Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. Proteomics 6, 1038-1048.
27. Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, et al,. (2009) Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics 8, 1278-1294.
28. Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow ME, et al,. (2012) Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res 14, R45.
29. Hochgrafe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, et al,. (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res 70, 9391-9401.
30. Chappell DS, Patel NA, Jiang K, Li P, Watson JE, Byers DM, &, Cooper DR, (2009) Functional involvement of protein kinase C-βII and its substrate, myristoylated alanine-rich C-kinase substrate (MARCKS), in insulin-stimulated glucose transport in L6 rat skeletal muscle cells. Diabetologia 52, 901-911.
31. Cowley MJ, Pinese M, Kassahn KS, Waddell N, Pearson JV, Grimmond SM, Biankin AV, Hautaniemi S, &, Wu J, (2012) PINA v2.0: mining interactome modules. Nucleic Acids Res 40, D862-D865.
32. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V, &, Sullivan M, (2012) PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 40, D261-D270.
33. Wu J, Vallenius T, Ovaska K, Westermarck J, Makela TP, &, Hautaniemi S, (2009) Integrated network analysis platform for protein-protein interactions. Nat Methods 6, 75-77.
34. Wu B, Zhang F, Yu M, Zhao P, Ji W, Zhang H, Han J, &, Niu R, (2012) Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells. Cell Prolif 45, 189-198.
35. Hiscox S, Jordan NJ, Morgan L, Green TP, &, Nicholson RI, (2007) Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis 24, 157-167.
36. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, &, Nicholson RI, (2004) Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis 21, 201-212.
37. Millar EK, Anderson LR, McNeil CM, O'Toole SA, Pinese M, Crea P, Morey AL, Biankin AV, Henshall SM, Musgrove EA, et al,. (2009) BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Br J Cancer 100, 123-133.
38. Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, et al,. (2009) Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene 28, 1812-1820.
39. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, &, Szallasi Z, (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123, 725-731.
40. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, et al,. (2011) Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 12, 924-938.
41. Radtke S, Milanovic M, Rosse C, de Rycker M, Lachmann S, Hibbert A, Kermorgant S, &, Parker PJ, (2013) ERK2 but not ERK1 mediates HGF-induced motility in non small cell lung carcinoma cell lines. J Cell Sci 126, 2381-2391.
42. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, Wessels LF, Neefjes J, Stal O, Linn SC, et al,. (2011) PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 125, 1-12.
43. Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, &, Isacke CM, (2010) Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 29, 4648-4657.
44. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, &, Rosen N, (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71.
45. Nipp M, Elsner M, Balluff B, Meding S, Sarioglu H, Ueffing M, Rauser S, Unger K, Hofler H, Walch A, et al,. (2012) S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging. J Mol Med 90, 163-174.
46. Sayeed S, Asano E, Ito S, Ohno K, Hamaguchi M, &, Senga T, (2013) S100A10 is required for the organization of actin stress fibers and promotion of cell spreading. Mol Cell Biochem 374, 105-111.
47. Zhang J, Guo B, Zhang Y, Cao J, &, Chen T, (2010) Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion. Saudi Med J 31, 374-381.
48. Chen X, &, Rotenberg SA, (2010) PhosphoMARCKS drives motility of mouse melanoma cells. Cell Signal 22, 1097-1103.
49. Neel DS, &, Bivona TG, (2013) Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clin Cancer Res 19, 3-5.
50. Ramsden JJ, (2000) MARCKS: a case of molecular exaptation? Int J Biochem Cell Biol 32, 475-479.
51. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, &, Guha A, (2009) Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res 69, 7548-7556.
52. Techasen A, Loilome W, Namwat N, Takahashi E, Sugihara E, Puapairoj A, Miwa M, Saya H, &, Yongvanit P, (2010) Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway. Cancer Sci 101, 658-665.
53. Kalwa H, &, Michel T, (2011) The MARCKS protein plays a critical role in phosphatidylinositol 4,5-bisphosphate metabolism and directed cell movement in vascular endothelial cells. J Biol Chem 286, 2320-2330.
54. Jin Cho S, La M, Ahn JK, Meadows GG, &, Joe CO, (2001) Tob-mediated cross-talk between MARCKS phosphorylation and ErbB-2 activation. Biochem Biophys Res Commun 283, 273-277.
55. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, &, Nicholson RI, (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97, 263-274.
56. Masaki T, Tokuda M, Yoshida S, Nakai S, Morishita A, Uchida N, Funaki T, Kita Y, Funakoshi F, Nonomura T, et al,. (2005) Comparison study of the expressions of myristoylated alanine-rich kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Int J Oncol 26, 661-671.
57. Jarboe JS, Anderson JC, Duarte CW, Mehta T, Nowsheen S, Hicks PH, Whitley AC, Rohrbach TD, McCubrey RO, Chiu S, et al,. (2012) MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res 18, 3030-3041.
58. Li T, Li D, Sha J, Sun P, &, Huang Y, (2009) MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383, 280-285.
59. Park J, Meisler AI, &, Cartwright CA, (1993) c-Yes tyrosine kinase activity in human colon carcinoma. Oncogene 8, 2627-2635.
60. Barraclough J, Hodgkinson C, Hogg A, Dive C, &, Welman A, (2007) Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells. Neoplasia 9, 745-754.
61. Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, et al,. (2009) Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol 3, 248-261.
62. Carr HS, Zuo Y, Oh W, &, Frost JA, (2013) Regulation of FAK activation, breast cancer cell motility and amoeboid invasion by the RhoA GEF Net1. Mol Cell Biol 33, 2773-2786.
63. Steinestel K, Bruderlein S, Steinestel J, Markl B, Schwerer MJ, Arndt A, Kraft K, Propper C, &, Moller P, (2012) Expression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis. PLoS One 7, e40671.
64. Zhang JY, Wang Y, Zhang D, Yang ZQ, Dong XJ, Jiang GY, Zhang PX, Dai SD, Dong QZ, Han Y, et al,. (2010) δ-Catenin promotes malignant phenotype of non-small cell lung cancer by non-competitive binding to E-cadherin with p120ctn in cytoplasm. J Pathol 222, 76-88.
65. Roberts CG, Millar EK, O'Toole SA, McNeil CM, Lehrbach GM, Pinese M, Tobelmann P, McCloy RA, Musgrove EA, Sutherland RL, et al,. (2011) Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene 30, 3186-3197.
66. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, &, Mann M, (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 10, 1794-1805.
67. Wu J, Mao X, Cai T, Luo J, &, Wei L, (2006) KOBAS server: a web-based platform for automated annotation and pathway identification. Nucleic Acids Res 34, W720-W724.
68. Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY, &, Wei L, (2011) KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res 39, W316-W322.
69. Benjamini Y, &, Yekutieli D, (2001) The control of the false discovery rate in multiple testing under dependency. Ann Stat 29, 1165-1188.
70. Smoot ME, Ono K, Ruscheinski J, Wang PL, &, Ideker T, (2011) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27, 431-432.
71. Janes PW, Daly RJ, deFazio A, &, Sutherland RL, (1994) Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9, 3601-3608.